0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IDH1

IDH1

IDH1 Molecule Information

Name:Isocitrate dehydrogenase [NADP] cytoplasmic
Target Synonym:Oxalosuccinate decarboxylase;Isocitrate dehydrogenase [NADP] cytoplasmic;IDP;Cytosolic NADP-isocitrate dehydrogenase;IDH1;PICD;NADP(+)-specific ICDH;IDH
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Approved

IDH1 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
ID1-H5120 Human Human IDH1 Protein, His Tag
ID1-H5120-structure
ID1-H5120-sds

IDH1 Molecule Synonym Name

IDH1,PICD,IDP

IDH1 Molecule Background

Isocitrate dehydrogenase 1 (IDH1) is also known as Cytosolic NADP-isocitrate dehydrogenase (NADP(+)-specific ICDH), Oxalosuccinate decarboxylase and PICD, which is one of the Isocitrate dehydrogenases that can catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD+ as the electron acceptor and the other NADP+. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production.

IDH1 References

IDH1 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Ivosidenib AG-120,AG120 Approved Agios Pharmaceuticals, Celgene, CStone Pharmaceuticals TIBSOVO fda AGIOS PHARMS INC 2018-07-20 Acute myeloid Leukemia (AML) Details

IDH1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BAY-1436032 BAY-1436032 Phase Ⅰ Bayer Solid tumours, Acute myeloid Leukemia (AML) Details
IDH1 peptide vaccine (German Cancer Research Center) Phase Ⅰ German cancer research center Glioma Details
IDH-305 IDH-305,IDH305 Phase Ⅱ Novartis Glioma, Acute myeloid Leukemia (AML), Malignancies Details
Vorasidenib AG-881,AG881 Phase Ⅰ Agios Pharmaceuticals, Celgene Glioma, Solid tumours, Hematological cancer Details
DS-1001 DS-1001; DS-1001b Phase Ⅰ Daiichi Sankyo Glioma Details
Olutasidenib FT-2102,FT 2102 Phase Ⅱ FORMA Therapeutics Myelodysplastic syndrome (MDS), Acute myeloid Leukemia (AML) Details
HMPL-306 HMPL-306 Phase Ⅰ Hutchison Medipharma Solid tumours, Hematological cancer Details

This web search service is supported by Google Inc.

totop